Loading
A review of how T cells already present in a patient's blood or tumour can be found, grown and made to work better as a cancer treatment.
The review presents endogenous T cells derived from peripheral blood or tumour sites as a source of effector cells for adoptive therapy, and covers strategies to isolate, manipulate and enhance antigen-specific T cells in vitro and to improve their efficacy and persistence in vivo by host immunomodulation (Immunological Reviews 2014).
An overview of the endogenous T-cell approach from one of its developers, written as checkpoint inhibitors and engineered cell therapies were entering the clinic.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Shares Endogenous T-cell therapy, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/